Novel janus kinase 3 inhibitor ritlecitinib suppresses T and B cell responses to prevent acute cardiac allograft rejection in mice
Clinical Immunology · 2025
DOI: 10.1016/j.clim.2025.110445 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Immunology, 2025. Verfasst von Rumin Liu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Transplantation, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China. Hauptthemen laut MEDLINE: Graft Rejection, Heart Transplantation, B-Lymphocytes, Janus Kinase 3. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben.
Abstract (Originalsprache)
Acute rejection is the main contributor to early allograft failure. Current immunosuppressive regimens have shortcomings, such as toxicity and minimal inhibitory effects on B cells. Hence, developing novel, effective, and selective anti-acute rejection drugs is crucial. Therefore, this study aimed to investigate the inhibitory effect of ritlecitinib (PF-06651600), a new janus kinase 3 inhibitor, on T and B cells, as well its preventive effects on acute allograft rejection. A murine cardiac transplantation model coupled with cell culture- and immunohistochemistry-based techniques was used. In vitro assays demonstrated that ritlecitinib inhibits naïve CD4+ T cell differentiation into T helper (Th)1 and Th17 cells, reduces relative inflammatory cytokines, and suppresses CD4+ and CD8+ T cell proliferation. Furthermore, ritlecitinib inhibited B cell activation and differentiation and antibody production. In vivo experiments revealed that ritlecitinib significantly prolongs allograft survival, decreases serum donor-specific antibody immunoglobulin G levels, alleviats allograft damage, and reduces C4d deposition and T, B, and plasma cell infiltration in allografts. Moreover, B and plasma cell percentages and counts were significantly decreased in recipient spleen, lymph nodes, bone marrow, and blood. Overall, ritlecitinib prevented acute rejection in cardiac transplantation by inhibiting T and B cells, suggesting its potential as a novel clinical immunosuppressant.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Transplantation, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
- Department of Pharmacy, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
- Department of Transplantation, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China. Electronic address: liaot@mail2.sysu.edu.cn.
- Department of Transplantation, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China. Electronic address: miaoyunecho@126.com.
Zitieren
APA
Liu, R., Shi, X., Zeng, W., Wang, Y., Yan, Z., Deng, W., Hui, J., Xia, R., Mo, L., Xu, J., Liao, T., & Miao, Y. (2025). Novel janus kinase 3 inhibitor ritlecitinib suppresses T and B cell responses to prevent acute cardiac allograft rejection in mice. Clinical Immunology. https://doi.org/10.1016/j.clim.2025.110445
Vancouver
Liu R, Shi X, Zeng W, Wang Y, Yan Z, Deng W, et al. Novel janus kinase 3 inhibitor ritlecitinib suppresses T and B cell responses to prevent acute cardiac allograft rejection in mice. Clinical Immunology. 2025. doi:10.1016/j.clim.2025.110445
BibTeX
@article{Liu2025,
author = {Liu, Rumin and Shi, Xiaoyi and Zeng, Wenli and Wang, Yuchen and Yan, Ziyan and Deng, Wenfeng and Hui, Jialiang and Xia, Renfei and Mo, Liqian and Xu, Jian and Liao, Tao and Miao, Yun},
title = {Novel janus kinase 3 inhibitor ritlecitinib suppresses T and B cell responses to prevent acute cardiac allograft rejection in mice},
journal = {Clinical Immunology},
year = {2025},
doi = {10.1016/j.clim.2025.110445}
}
EUVIMED